Boundless Bio is reducing workforce by one-third and focusing on combination therapy, aiming for innovation.
From Nasdaq: 2025-05-23 17:51:00 Boundless Bio (BOLD) plans to reduce its workforce by one-third to streamline operations. It will discontinue
